Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis

Source Summary

Oxford, UK and Boston, MA – 22 June 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced the completion of enrollment in its Phase 1b clinical trial of SYX-5219, a first-in-class, oral pyruvate kinase M2 (PKM2) modulator, in adults with moderate to severe atopic dermatitis.